Aethlon Medical (NASDAQ: AEMD) shares are up 260% in the last 5 days.
This article looks into the emerging value proposition of Aethlon Medical, Inc. We explain the history of the company, what it does, why it is surging in value and the best places to buy AEMD stock in the UK and elsewhere.
How and where to buy Aethlon Medical shares
If you want to invest in AEMD shares, you should sign up to a reliable and trustworthy stockbroker, deposit some funds, and search for AEMD stock on the platform’s interface.
To save you some time, we have listed the two best stockbrokers of 2021 below:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Aethlon Medical?
Founded in 1998 and headquartered in San Diego, California, it is a medical technology company that is focussed on developing products to diagnose and treat life and organ threatening diseases in the United States.
It is developing two main products: the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device, and TauSome, an exosomal biomarker candidate.
Why is AEMD stock on the rise?
Because of a surge in volume and rumours that it could be involved in a pioneering COVID-19 treatment.
Should I buy AEMD shares?
If you want to invest in a high-risk medical tech company with potentially sizeable rewards, Aethlon Medical shares could be an asset to consider closely.
The company still has a long way to go to commercialise some of its technologies, and while the road is unlikely to be smooth, there is definite inherent value in some of the company’s products, thinking and general medical expertise.
AEMD price target
Our Aethlon Medical price prediction previously aligned nicely with that of most top analysts: a 12-month high of $6, median of $5.50 and low of $5.
However, given the rumours that are driving this price action have propelled the stock to over $10, it remains to be seen if anything concrete materialises in the coming days that could reshape these projections.